Study With Phage for CF Subjects With Pseudomonas Lung Infection

PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Chronic Pseudomonas Aeruginosa InfectionCystic Fibrosis (CF)
Interventions
BIOLOGICAL

BX004

Bacteriophage

OTHER

Placebo

Placebo

Trial Locations (14)

10028

RECRUITING

Northwell Health, New York

10593

RECRUITING

New York Medical College, Hawthorne

32503

RECRUITING

Avanza Medical Center, Pensacola

32803

RECRUITING

Central Florida Pulmonary Group, Orlando

33021

NOT_YET_RECRUITING

Joe DiMaggio Children's Health, Hollywood

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

72205

NOT_YET_RECRUITING

University of Arkansas for Medical Sciences, Little Rock

80206

RECRUITING

National Jewish Health, Denver

84132

NOT_YET_RECRUITING

University of Utah, Salt Lake City

94061

NOT_YET_RECRUITING

Stanford University, Palo Alto

94143

RECRUITING

University of California San Francisco, San Francisco

99508

NOT_YET_RECRUITING

Providence Alaska Medical Center, Anchorage

08901

RECRUITING

Rutgers, Robert Wood Johnson Medical School, New Brunswick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BiomX Ltd

INDUSTRY

NCT06998043 - Study With Phage for CF Subjects With Pseudomonas Lung Infection | Biotech Hunter | Biotech Hunter